These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 28259679)

  • 1. A pH-responsive glycolipid-like nanocarrier for optimising the time-dependent distribution of free chemical drugs in focal cells.
    Cheng B; Lu B; Liu X; Meng T; Tan Y; Zhu Y; Liu N; Yuan H; Huang X; Hu F
    Int J Pharm; 2017 Apr; 522(1-2):210-221. PubMed ID: 28259679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective redox-responsive drug release in tumor cells mediated by chitosan based glycolipid-like nanocarrier.
    Hu YW; Du YZ; Liu N; Liu X; Meng TT; Cheng BL; He JB; You J; Yuan H; Hu FQ
    J Control Release; 2015 May; 206():91-100. PubMed ID: 25796347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles.
    Hu FQ; Liu LN; Du YZ; Yuan H
    Biomaterials; 2009 Dec; 30(36):6955-63. PubMed ID: 19782395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Redox-responsive polymer-drug conjugates based on doxorubicin and chitosan oligosaccharide-g-stearic acid for cancer therapy.
    Su Y; Hu Y; Du Y; Huang X; He J; You J; Yuan H; Hu F
    Mol Pharm; 2015 Apr; 12(4):1193-202. PubMed ID: 25751168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance.
    Meng T; Lu B; Shao S; Yuan M; Liu X; Yuan H; Huang X; Hu F
    Int J Pharm; 2017 Dec; 534(1-2):368-377. PubMed ID: 29051118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced cytotoxicity of core modified chitosan based polymeric micelles for doxorubicin delivery.
    Ye YQ; Chen FY; Wu QA; Hu FQ; Du YZ; Yuan H; Yu HY
    J Pharm Sci; 2009 Feb; 98(2):704-12. PubMed ID: 18563810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A54 Peptide Modified and Redox-Responsive Glucolipid Conjugate Micelles for Intracellular Delivery of Doxorubicin in Hepatocarcinoma Therapy.
    Liu N; Tan Y; Hu Y; Meng T; Wen L; Liu J; Cheng B; Yuan H; Huang X; Hu F
    ACS Appl Mater Interfaces; 2016 Dec; 8(48):33148-33156. PubMed ID: 27934140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular uptake and cytotoxicity of shell crosslinked stearic acid-grafted chitosan oligosaccharide micelles encapsulating doxorubicin.
    Hu FQ; Wu XL; Du YZ; You J; Yuan H
    Eur J Pharm Biopharm; 2008 May; 69(1):117-25. PubMed ID: 17997293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chitosan Immobilization on Bio-MOF Nanostructures: A Biocompatible pH-Responsive Nanocarrier for Doxorubicin Release on MCF-7 Cell Lines of Human Breast Cancer.
    Abazari R; Mahjoub AR; Ataei F; Morsali A; Carpenter-Warren CL; Mehdizadeh K; Slawin AMZ
    Inorg Chem; 2018 Nov; 57(21):13364-13379. PubMed ID: 30351060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pH triggered doxorubicin delivery of PEGylated glycolipid conjugate micelles for tumor targeting therapy.
    Hu FQ; Zhang YY; You J; Yuan H; Du YZ
    Mol Pharm; 2012 Sep; 9(9):2469-78. PubMed ID: 22827551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chitosan-tripolyphosphate nanoparticles functionalized with a pH-responsive amphiphile improved the in vitro antineoplastic effects of doxorubicin.
    Nogueira-Librelotto DR; Scheeren LE; Vinardell MP; Mitjans M; Rolim CMB
    Colloids Surf B Biointerfaces; 2016 Nov; 147():326-335. PubMed ID: 27543694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of chitosan based glycolipid-like nanocarrier in prevention of developing acquired drug resistance in tri-cycle treatment of breast cancer.
    Meng T; Qiu G; Hong Y; Yuan M; Lu B; Wu J; Yuan H; Hu F
    Int J Pharm; 2019 Jan; 555():303-313. PubMed ID: 30471372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chitosan oligosaccharide-arachidic acid-based nanoparticles for anti-cancer drug delivery.
    Termsarasab U; Cho HJ; Kim DH; Chong S; Chung SJ; Shim CK; Moon HT; Kim DD
    Int J Pharm; 2013 Jan; 441(1-2):373-80. PubMed ID: 23174411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linoleic acid-grafted chitosan oligosaccharide micelles for intracellular drug delivery and reverse drug resistance of tumor cells.
    Du YZ; Wang L; Yuan H; Hu FQ
    Int J Biol Macromol; 2011 Jan; 48(1):215-22. PubMed ID: 21093477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stepwise pH-responsive nanoparticles for enhanced cellular uptake and on-demand intracellular release of doxorubicin.
    Chen WL; Li F; Tang Y; Yang SD; Li JZ; Yuan ZQ; Liu Y; Zhou XF; Liu C; Zhang XN
    Int J Nanomedicine; 2017; 12():4241-4256. PubMed ID: 28652730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemosensitizing indomethacin-conjugated chitosan oligosaccharide nanoparticles for tumor-targeted drug delivery.
    Lee JY; Termsarasab U; Lee MY; Kim DH; Lee SY; Kim JS; Cho HJ; Kim DD
    Acta Biomater; 2017 Jul; 57():262-273. PubMed ID: 28483700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors.
    Butt AM; Amin MC; Katas H; Abdul Murad NA; Jamal R; Kesharwani P
    Mol Pharm; 2016 Dec; 13(12):4179-4190. PubMed ID: 27934479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved cytotoxicity and multidrug resistance reversal of chitosan based polymeric micelles encapsulating oxaliplatin.
    Xu YY; Du YZ; Yuan H; Liu LN; Niu YP; Hu FQ
    J Drug Target; 2011 Jun; 19(5):344-53. PubMed ID: 20854014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simply constructed chitosan nanocarriers with precise spatiotemporal control for efficient intracellular drug delivery.
    Kong M; Zuo Y; Wang M; Bai X; Feng C; Chen X
    Carbohydr Polym; 2017 Aug; 169():341-350. PubMed ID: 28504154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PEGylated and poloxamer-modified chitosan nanoparticles incorporating a lysine-based surfactant for pH-triggered doxorubicin release.
    Scheeren LE; Nogueira DR; Macedo LB; Vinardell MP; Mitjans M; Infante MR; Rolim CM
    Colloids Surf B Biointerfaces; 2016 Feb; 138():117-27. PubMed ID: 26674840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.